+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Philippines OTC Pharmaceutical Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 120 Pages
  • April 2024
  • Region: Philippines
  • Expert Market Research
  • ID: 5960402

Philippines OTC Pharmaceutical Market Overview

The Philippines over the counter (OTC) pharmaceuticals market is estimated to grow at a compound annual growth rate (CAGR) of 5.2% during the forecast period of 2024-2032.The market is driven by the increasing demand for self-medication, the rising prevalence of chronic and lifestyle diseases, the growing awareness and accessibility of OTC products, and the favorable government policies and regulations.

Philippines OTC Pharmaceutical Market Drivers and Constraints

  • The increasing demand for self-medication is one of the major drivers of the OTC pharmaceuticals market in the Philippines. The consumers are becoming more health-conscious and empowered to manage their own health conditions, especially for minor ailments and common symptoms. The availability and affordability of OTC products, as well as the convenience and time-saving benefits of self-medication, are also encouraging the consumers to opt for OTC products.
  • The rising prevalence of chronic and lifestyle diseases, such as diabetes, hypertension, cardiovascular diseases, respiratory diseases, and obesity, is another key driver of the market. These diseases require long-term and continuous treatment, which can be costly and inconvenient for the patients. OTC products can provide an alternative and complementary option for the patients to manage their symptoms and improve their quality of life.
  • The growing awareness and accessibility of OTC products is also a significant driver of the market. The consumers are becoming more informed and educated about the benefits, safety, and efficacy of OTC products, thanks to the various promotional and educational campaigns by the government, the industry, and the media. The accessibility of OTC products is also improving, as they are widely distributed through various channels, such as pharmacies, drugstores, supermarkets, convenience stores, and online platforms.
  • The favorable government policies and regulations are also supporting the growth of the OTC pharmaceuticals market in the Philippines. The government has implemented several initiatives to promote the rational use of OTC products, such as the Generics Act of 1988, the Philippine National Drug Formulary, the Food and Drug Administration Act of 2009, and the Universal Health Care Act of 2019. These initiatives aim to ensure the quality, safety, and affordability of OTC products, as well as to increase the access and coverage of health care services for the population.
  • The lack of awareness and trust in some OTC products, especially among the rural and low-income segments, is also a barrier for the market growth. The regulatory uncertainties and barriers, such as the lengthy and complex approval process, the frequent changes in the classification and labeling of OTC products, and the lack of harmonization with the regional and international standards, are also hindering the market development. The counterfeit and substandard products, which pose a threat to the health and safety of the consumers, as well as to the reputation and credibility of the industry, are also a challenge for the market.

Philippines OTC Pharmaceutical Market Trends and Developments

  • Rising Health Awareness: There is a growing trend of self-medication among Filipinos, driven by increasing health consciousness and easy access to information about health and wellness through the internet and social media.
  • Expanding Middle Class: The expanding middle class in the Philippines, with higher disposable incomes, is more inclined to spend on healthcare products, including OTC medications, for maintaining health and preventing illness.
  • Growth of Pharmacy Retail Chains: The expansion of pharmacy retail chains across the country is improving the availability and accessibility of OTC pharmaceuticals, contributing to market growth.
  • Digital Transformation: The rise of e-commerce and online pharmacies is making it easier for consumers to purchase OTC medications, with the convenience of home delivery and online consultations.
  • Regulatory Environment: The Philippine Food and Drug Administration (FDA) plays a crucial role in regulating OTC pharmaceuticals, ensuring product safety and efficacy. Recent regulatory reforms and streamlined processes are expected to positively impact the market.
  • Increasing Demand for Herbal and Natural Products: There is a growing preference for herbal and natural OTC products, driven by the perception of fewer side effects and a focus on holistic wellness.
  • Product Innovation and Diversification: Manufacturers are continuously innovating and diversifying their product offerings to meet consumer demand for a wide range of OTC medications, including those for pain relief, cold and flu, digestive health, and vitamins and supplements.
  • Health and Wellness Trends: The increasing focus on preventive healthcare and wellness is driving the demand for OTC products that support immune health, energy levels, and overall well-being.

Philippines OTC Pharmaceutical Market Segmentation

Market Breakup by Product Type

  • Pain Relievers
  • Anti-allergic
  • Gastrointestinal Drugs
  • Vitamins and Minerals
  • Cough and Cold Remedies
  • Others

Market Breakup by Distribution Channel

  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Market Breakup by Formulation Type

  • Tablets
  • Liquids
  • Ointments
  • Sprays

Philippines OTC Pharmaceutical Market: Competitive Landscape

The OTC pharmaceuticals market in the Philippines is highly competitive and fragmented, with the presence of several local and international players. The key players in the market include Johnson & Johnson, GlaxoSmithKline, Bayer AG, Pfizer Inc., Sanofi, Novartis International AG, Procter & Gamble, Reckitt Benckiser Group plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Teva Pharmaceutical Industries Ltd., Mylan N.V. (now part of Viatris Inc.) and Cipla Limited.

These players compete on the basis of product quality, safety, efficacy, price, innovation, distribution, marketing, and customer service. The key players also engage in various strategic initiatives, such as mergers and acquisitions, joint ventures, partnerships, collaborations, product launches, expansions, and investments, to strengthen their market position and expand their market share.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Philippines OTC Pharmaceutical Market Overview
3.1 Philippines OTC Pharmaceutical Market Historical Value (2017-2023)
3.2 Philippines OTC Pharmaceutical Market Forecast Value (2024-2032)
4 Philippines OTC Pharmaceutical Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.2.1 Strengths
4.2.2 Weaknesses
4.2.3 Opportunities
4.2.4 Threats
4.3 Porter’s Five Forces Model
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Buyers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitutes
4.3.5 Degree of Rivalry
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Philippines OTC Pharmaceutical Market Segmentation
5.1 Philippines OTC Pharmaceutical Market by Product Type
5.1.1 Market Overview
5.1.2 Pain Relievers
5.1.3 Anti-allergic
5.1.4 Gastrointestinal Drugs
5.1.5 Vitamins and Minerals
5.1.6 Cough and Cold Remedies
5.1.7 Others
5.2 Philippines OTC Pharmaceutical Market by Distribution Channel
5.2.1 Retail Pharmacies
5.2.2 Online Pharmacies
5.2.3 Drug Stores
5.3 Philippines OTC Pharmaceutical Market by Formulation Type
5.3.1 Market Overview
5.3.2 Tablets
5.3.3 Liquids
5.3.4 Ointments
5.3.5 Sprays
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication Year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by Year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaboration Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 Johnson & Johnson
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 GlaxoSmithKline
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 Bayer AG
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 Pfizer Inc.
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Sanofi
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 Novartis International AG
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 Procter & Gamble
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 Reckitt Benckiser Group plc
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 Takeda Pharmaceutical Company Limited
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Boehringer Ingelheim
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 Sun Pharmaceutical Industries Ltd.
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Perrigo Company plc
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Mylan N.V. (now part of Viatris Inc.)
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Cipla Limited
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Philippines OTC Pharmaceutical Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
15.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The research team strives to make this section as comprehensive as possible.

Companies Mentioned

  • Johnson & Johnson
  • GlaxoSmithKline
  • Bayer AG
  • Pfizer Inc.
  • Sanofi
  • Novartis International AG
  • Procter & Gamble
  • Reckitt Benckiser Group plc
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim
  • Sun Pharmaceutical Industries Ltd.
  • Perrigo Company plc
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V. (now part of Viatris Inc.)
  • Cipla Limited

Methodology

Loading
LOADING...